Capricor Therapeutics Faces Investor Fraud Investigations Following Severe Stock Crash

New York, Sunday, 2 August 2026.
Law firms are investigating Capricor Therapeutics for potential securities fraud after undisclosed trial plan changes triggered a 64% stock crash following an adverse FDA efficacy report.